Document and Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Mar. 24, 2025 |
Jun. 30, 2024 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Document Fiscal Year Focus | 2024 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Interactive Data Current | Yes | ||
| Trading Symbol | FBRX | ||
| Entity Current Reporting Status | Yes | ||
| Entity Registrant Name | FORTE BIOSCIENCES, INC. | ||
| Entity Central Index Key | 0001419041 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Shell Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Title of 12(b) Security | Common Stock | ||
| Security Exchange Name | NASDAQ | ||
| Entity File Number | 001-38052 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 26-1243872 | ||
| Entity Address, Address Line One | 3060 Pegasus Park Drive, Building 6 | ||
| Entity Address, City or Town | Dallas | ||
| Entity Address, State or Province | TX | ||
| Entity Address, Postal Zip Code | 75247 | ||
| City Area Code | 310 | ||
| Local Phone Number | 618-6994 | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Entity Public Float | $ 18.3 | ||
| Entity Common Stock, Shares Outstanding | 6,581,667 | ||
| Auditor Name | KPMG LLP | ||
| Auditor Firm ID | 185 | ||
| Auditor Location | San Diego, California | ||
| Auditor Opinion | Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Forte Biosciences, Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. |
||
| Documents Incorporated by Reference | Portions of the Registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, subsequent to the date hereof pursuant to Regulation 14A in connection with the Registrant’s 2025 Annual Meeting of Stockholders will be incorporated by reference into Part III of this Annual Report on Form 10-K assuming such proxy statement is filed with the SEC not later than 120 days after the conclusion of the registrant’s fiscal year ended December 31, 2024. If such proxy statement is not filed on or before such date, the information called for by Part III will be filed as part of an amendment to this Annual Report on Form 10-K on or before such date. |